Oestrogenic effects in hormone responsive tissues such as the breast include induction of protein synthesis as well as increased proliferation. In addition, oestrogens appear to play an important role in the development, maintenance and growth of breast tumours. The currently held hypothesis is that these oestrogenic effects are mediated through the interaction of hormone and specific nuclear oestrogen receptor (ER). While the presence of specific oestrogen and progesterone (PR) receptors appears to be an important determinant of response to hormone treatment (Whitliff, 1983; Cant et al., 1985; Vollenweider-Zerargul et al., 1986; Williams et al., 1987) , in breast cancer not all receptor positive tumours are amenable to hormonal manipulation. However, absence of receptor is associated with a low probability of response to hormone therapy.
Apart from the utility of receptors as predictors for response to hormonal treatment an important pathopysiological consideration in breast cancer is the influence of endogenous hormones on tumour genesis, promotion and growth. These effects are also thought to be mediated through the receptor mechanism. Steroid receptors are, however, demonstrated only in a proportion of breast cancers (Allegra et al., 1979; Mohla et al., 1982; McGuire et al., 1984) . Whether receptor negative tumours are independent of hormonal influence requires elucidation.
Recently two oestrogen regulated proteins, P24 (Edwards et al., 1981; Ciocca et al., 1982 Ciocca et al., , 1984 Adams et al., 1983; Adams & McGuire, 1985) and P52 (Veith et al., 1983; Garcia et al., 1984 Garcia et al., , 1985 Rochefort et al., 1987) P24 immunocytochemistry Frozen sections were placed on HCI-ethanol cleaned slides. Specimens were fixed by immersion in 3.7% formalin for 10 minutes followed by ice cold methanol for 4 minutes and then in ice cold acetone for 1-2 minutes. Slides were rinsed with cold phosphate-buffered saline (PBS) and immersed in H202 -methanol (to block endogenous peroxidase) and then rinsed again. Thereafter slides were incubated for 3 hours with monoclonal anti-P24 antibody (5pg ml-') (Ciocca et al., 1983a) (King et al., 1985; Thorpe, 1987) (Abbot Laboratories) according to the manufacturers' instructions. Immunocytochemical staining for PR was performed according to previously described methods (Logeat et al., 1983; Perrot-Applanat, 1985 , 1987 Apart from the pretreatment investigations 24 patients were investigated serially during the course of a randomised ongoing study of the effects of hormone priming before chemotherapy. Patients were eligible for this study whether ER + or ER -and were randomly allocated to receive either hormone priming followed by chemotherapy or chemotherapy alone. Nineteen of the 24 patients had been randomised to the hormone priming arm and were evaluated following a short exposure to oestrogen (given as diethylstilboestrol 5 mg day-' x 5 days). Biopsies were performed immediately before and immediately after hormone administration. Five patients were evaluated before and after chemotherapy without any prior hormonal priming.
The study was approved by the Ethics Committee of the University of the Witwatersrand and was carried out in accordance with the principles of the Declaration of Helsinki.
Results
The results using the histocytochemical assays were highly reproducible. Inter and intra-observer variation was minimal with a correlation coefficient of >0.9 for single biopsy specimens. When multiple simultaneous biopsies were carried out on the same patient (19 patients had multiple simultaneous biopsies) the overall scores, taking into account 10 fields from each biopsy sample, were also consistent with a correlation coefficient >0.9.
Approximately 50% of samples obtained before therapy showed positive staining for P24 (Table I ). There were no significant differences in the proportion showing P24 staining when black or white patients, those with aneuploid or diploid tumours, or PR positive and PR negative tumours were compared. P24 staining was, however, found to be (Table II) . Of the 13 tumours that were P24 negative before hormone treatment seven became positive for P24 after oestrogen administration. P24 induction was noted in 6/9 ER negative as well as 1/4 in ER positive tumours.
Oestrogenic stimulation of cell growth (as defined by an increase of proliferative index >10% from base line values) was seen in 12/19 patients given a short course of diethylstilboestrol. The 12 tumours which showed an increase of proliferation index after oestrogen treatment included 5/7 that were ER positive and 7/12 that were ER negative before hormone administration.
The relationships between P24 expression and alteration of proliferation index were also complex. Proliferation index increased in 3/6 tumours that were initially P24 positive and in 9/13 that were initially P24 negative. Among the tumours that were initially P24 positive, two showed increased proliferation together with loss of P24 expression while one remained p24 positive within increased proliferation following oestrogen. On the other hand, among the nine tumours that were initially P24 negative and which showed an increase in proliferation index, six had P24 induction with increased proliferation while three showed an increase in proliferation with P24 remaining negative. In two instances there was a significant decrease of proliferation index following 5 days of diethylstilboestrol therapy. Both were tumours that were ER + and PR-and in both instances PR was induced by oestrogen exposure together with the decrease of proliferation index. In addition P24 expression was also induced in one of these tumours.
The effects of oestrogen administration on hormone receptor expression are shown in Table III 
Hormone receptors ER + PR + ER + PR-ER-PR+ ER-PRPretreatment
After oestrogen administration received chemotherapy only. Furthermore no instances of increase in proliferation index were observed following chemotherapy.
Discussion
The 24,000 Da protein, P24, was first detected in MCF-7 cells and appears from protein studies to be an oestrogen regulated (Edwards et al., 1981) secretory protein (Ciocca et al., 1982; Adams et al., 1983) . Following these initial investigations P24 has also been found in other oestrogen receptor positive cell lines (Ciocca et al., 1983b) as well as in highly oestrogen responsive target tissues such as human decidua (Ciocca et al., 1983c) and in certain cells of the female genital tract (Ciocca et al., 1983b) . Recent DNA sequencing studies have shown that the P24 protein is identical with a human heat shock protein, designated as hsp27, which was first detected in HeLa cells (Fuqua et al., 1990 (Hickey et al., 1986) . While the function of P24/hsp27 is unknown, the selective tissue expression and its apparent control by oestrogen suggested that P24 might be a useful marker for the study of oestrogen action in breast cancer, both as an indicator of endogenous hormonal action and possible as a predictor of hormone responsiveness. The correlation between initial oestrogen receptor status and P24 expression and between histological grade and P24 expression suggest that the expression of these biological tumour markers is in some way linked. In this regard the comparison between black and white patients is of some interest. Previous studies have suggested a lower frequency of receptor positive tumours among black women than among caucasian women (Savage et al., 1980; Mohla et al., 1982; Pegoraro et al., 1986) . A previous study from this institution (Dansey et al., 1988) demonstrated, however, that black patients with breast cancer have a significantly younger age distribution, thus raising the possibility of ER masking by endogenous oestrogens when ER estimations are performed by ligand binding methods. The study of P24 might thus offer a means of establishing the presence of endogenous hormone action in apparently ER-tumours. Consistent with this hypothesis the present study showed no significant differences between black and white subjects in regard to P24 expression. It should be pointed out, however, that in the present study, where immunocytochemical methods were used for ER and PR estimation, there were also no significant differences in ER or PR status between the two racial groups.
While the correlation between baseline P24 and ER status was significant, P24 expression was by no means confined to ER positive tumours. The presence of P24 in ER-tumours could be due to constitutive production of the protein by tumour cells or the induction of synthesis by oestrogen in the absence of detectable ER. In this regard the results following exposure to oestrogen have to be taken into account. Following oestrogen administration P24 induction was noted in 7/13 tumours previously negative for P24. There was, however, no correlation, in vivo, between ER content and oestrogen induced synthesis of P24.
The influence of diethylstiboesterol on cell proliferation appeared also to be independent of ER with both ER + and ER-tumours, showing an increase of proliferation as assessed by flow cytometric analysis. The validity of the flow cytometric measurements was confirmed by clinical observations which showed a highly significant correlation between clinical tumour flare and an increase in the proliferative index (x2 = 17.4, P<O.OOO1). Tumour flares following oestrogen administration occurred in ER -as well as in ER + patients.
The changes observed in hormone receptor expression following oestrogen exposure, on the other hand, did follow a pattern predicted by in vitro models, i.e. reduction of ER content and induction of PR expression (Nardulli et al., 1988) , which occurred only in ER positive tumours.
That these results were due to the administered oestrogen and not to sampling error is shown by the findings in those patients receiving chemotherapy only. There were no changes in either P24 or hormone receptor expression following chemotherapy without hormone priming. Furthermore, there was no instance of an increase in proliferation index following chemotherapy alone.
The patterns of response following in vivo oestrogen exposure were thus variable and included: (a) induction of new protein synthesis; (b) induction of new protein synthesis together with stimulation of proliferation; (c) stimulation of proliferation occurring without induction of new protein synthesis. While some of these effects, e.g. induction of PR synthesis, appear to be dependent on the presence of specific oestrogen receptor, increased proliferation of P24 synthesis can be induced by oestrogens in the apparent absence of specific ER. In this regard it should be pointed out that since receptor status was determined by demonstration of ER protein by means of immunological rather than ligand binding methods these results are unlikely to be due to receptor masking by high endogenous steroid levels (Thorpe, 1987) .
While it remains possible that oestrogenic effects were due to the presence of receptor at concentrations not detectable by current immunological techniques the possibility should be considered that oestrogens can exert significant effects in clinical breast cancer by mechanisms other than binding to specific ER.
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